Brandtree

Who owns medicube?

medicube is owned by APR (South Korea, KRX: 278470).[1]

This ownership is reported in official statements but has not yet been matched to a regulatory filing.

Evidence: APR Co., Ltd. Business Report (사업보고서) for fiscal year 2025, filed with DART, 23 March 2026. Last checked .

Key facts

Current owner
APR Co., Ltd. reported
Owner HQ
🇰🇷 South Korea, Seoul
Origin
🇰🇷 South Korea, Seoul
Founded
2016
Category
Personal care & beauty › Skin care › Dermocosmetics & clinical skin care
Parent ticker
KRX: 278470
Last verified
· 1 sources

About medicube

medicube is a dermocosmetic brand that APR launched in July 2016, with product lines arranged by skin concern and designed to work alongside the company's home beauty devices. Those devices, led by the Booster Pro, are sold as medicube AGE-R, a line APR started in March 2021 and makes at its own APR Factory plants. Devices brought in 407.0 billion won in 2025, 26.7 per cent of APR's revenue.

Ownership timeline of medicube

Owners of medicube over 2016 to 2026 APR start not recorded–present APR (start not recorded) 201620172018201920202021202220232024202520262027
  1. Current owner APR [1] reported

Where medicube sits in APR

Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.

Where medicube sits in APR Tree of 5 brands under APR. APR medicube aprilskin Forment Glam.D Nerdy

Open the full APR ownership tree →

See the full APR brand portfolio (5) →

Other brands owned by APR

APR controls 5 brands on Brandtree, 3 of them in personal care & beauty.

Also in personal care & beauty

Founded in the 2010s

All APR brands →

Other brands in dermocosmetics & clinical skin care, and who owns them

The 48 brands in dermocosmetics & clinical skin care on Brandtree belong to 27 owners. The largest is Ego Pharmaceuticals, with 9.

BrandOwnerOwner based in
DermAid Ego Pharmaceuticals 🇦🇺 Australia
Biretix Cantabria Labs 🇪🇸 Spain
CeraVe L'Oréal 🇫🇷 France
A-Derma Pierre Fabre 🇫🇷 France
Dermalogica Unilever 🇬🇧 United Kingdom
Minon Daiichi Sankyo Healthcare 🇯🇵 Japan
Alastin Galderma 🇨🇭 Switzerland
REALBARRIER Neopharm 🇰🇷 South Korea

Every brand in dermocosmetics & clinical skin care and its owner →

About the owner: APR

APR is a publicly listed company headquartered in Seoul, South Korea, founded in 2014. Brandtree records 5 brands under its control, and it is listed as KRX: 278470.

APR is a Seoul beauty company founded in October 2014 by Kim Byung-hoon, its chief executive and largest shareholder with 31.94 per cent of the shares at the end of 2025. It sells skin care, make-up and fragrance under medicube, aprilskin and Forment, and home beauty devices under medicube AGE-R, which its subsidiary APR Factory builds. Listed on KOSPI since February 2024, it had 2025 revenue of 1.53 trillion won, 80 per cent of it from outside Korea.

APR: full profile, brands and acquisition history →

🇰🇷 medicube and other South Korean brands

Brandtree records a controlling owner for 237 brands that began in South Korea. 12 of them (5%) are now controlled by a company headquartered in another country; medicube is not one of them.

All South Korean brands and who owns them →

Frequently asked questions

Who is the parent company of medicube?

The parent company of medicube is APR, a publicly listed company headquartered in South Korea.

Is medicube South Korean?

Yes. medicube originated in South Korea in 2016 and its owner, APR, is also headquartered in South Korea.

Is medicube still owned by APR?

Yes. As of 28 October 2026, medicube is still owned by APR. The ownership record was last checked against primary sources on that date.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] APR Co., Ltd. Business Report (사업보고서) for fiscal year 2025, filed with DART — APR Co., Ltd., Stock exchange filing, published 23 March 2026; retrieved 28 October 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.